NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
March 31, 2019
|
1.
|
Organization, Business
|
EyeGate Pharmaceuticals,
Inc. (“EyeGate” or the “Company”), a Delaware corporation, began operations in December 2004 and is a clinical-stage
specialty pharmaceutical company that is focused on developing and commercializing products for treating diseases and disorders
of the eye. The Company accomplishes this by leveraging its two proprietary platform technologies, crosslinked thiolated carboxymethyl
hyaluronic acid (“CMHA-S”) and the iontophoresis drug delivery system. The Company’s first platform is for the
development of products using CMHA-S, a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique
physical and chemical properties such as hydrating and healing properties when applied to the ocular surface. The ability of CMHA-S
to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various
ocular surface injuries. Secondly, the Company has been developing EGP-437, which incorporates a reformulated topically active
corticosteroid, Dexamethasone Phosphate, that is delivered into the ocular tissues through the Company’s proprietary innovative
drug delivery system, the EyeGate® II Delivery System (“EGP-437 Combination Product”).
As of March 31, 2019,
there were 45,575,737 shares of Common Stock outstanding, no shares of Series A Preferred Stock outstanding, no shares of Series
B Preferred Stock outstanding, and 4,092 shares of Series C Preferred Stock outstanding.
Since its inception,
EyeGate has devoted substantially all of its efforts to business planning, research and development, and raising capital.
The accompanying Condensed
Consolidated Financial Statements have been prepared assuming that EyeGate will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. At March 31, 2019, EyeGate had Cash
and Cash Equivalents of $5,855,966, and an Accumulated Deficit of $92,279,389. EyeGate has incurred losses and negative cash flows
since inception, and future losses are anticipated. The Company anticipates having sufficient cash to fund planned operations through
October 31, 2019, however, the acceleration or reduction of cash outflows by Company management can significantly impact the timing
for raising additional capital to complete development of its products. To continue development, EyeGate will need to raise additional
capital through equity financing, license agreements, and/or additional U.S. government grants. Although historically the Company
has been successful at raising capital, additional capital may not be available on terms favorable to EyeGate, if at all. On May
3, 2019, the Company filed a registration statement on Form S-3 to register a total of $50,000,000 of its securities for sale to
the public from time to time in what is known as a “shelf offering”. This filing is under review by the SEC and has
not yet been declared effective. The Company does not know if any future offerings, including offerings pursuant to its shelf registration
statement, will succeed. Accordingly, no assurances can be given that Company management will succeed in these endeavors. The Company’s
recurring losses from operations have caused management to determine there is substantial doubt about the Company’s ability
to continue as a going concern. The Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible
future effects on the recoverability and classification of assets or the amounts and classification of liabilities or any other
adjustments that might be necessary should the Company be unable to continue as a going concern.
EYEGATE PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
March 31, 2019
|
2.
|
Summary of Significant Accounting Policies
|
Basis of Presentation and Principles of Consolidation
The accompanying Condensed Consolidated
Financial Statements include the accounts of the Company and its subsidiaries, EyeGate Pharma S.A.S. and Jade Therapeutics, Inc.
(“Jade”), collectively referred to as “the Company”. All inter-company balances and transactions have been
eliminated in consolidation. These Condensed Consolidated Financial Statements have been prepared in accordance with accounting
principles generally accepted in the United States (“U.S. GAAP”) pursuant to the rules and regulations of the Securities
and Exchange Commission (“SEC”) for interim financial information. Certain information and disclosures normally included
in Condensed Consolidated Financial Statements prepared in accordance with U.S. GAAP have been condensed or eliminated. Accordingly,
these unaudited Condensed Consolidated Financial Statements should be read in conjunction with the annual financial statements
of the Company as of and for the year ended December 31, 2018.
Unaudited Interim Financial Information
The accompanying interim financial statements
and related disclosures are unaudited, have been prepared on the same basis as the annual financial statements and, in the opinion
of management, reflect all adjustments, which consist of normal recurring adjustments, necessary for a fair presentation of the
results of operations for the periods presented. The year-end balance sheet was derived from audited financial statements, but
does not include all disclosures required by U.S. GAAP. The results of operations for an interim period are not necessarily indicative
of the results to be expected for the full year or for any other future year or interim period.
Use of Estimates
The preparation of financial statements
in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts
of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements, and the
reported amounts of expenses during the reporting periods. The Company makes significant estimates and assumptions in recording
the accruals for its clinical trial and research activities, establishing the useful lives of intangible assets and property and
equipment, and conducting impairment reviews of long-lived assets. The Company bases its estimates on historical experience and
various other assumptions that it believes to be reasonable under the circumstances. Although the Company monitors and regularly
assesses these estimates, actual results could differ significantly from these estimates. The Company records changes in estimates
in the period that it becomes aware of the change.
Research and Development Expenses
The Company expenses research and development
(“R&D”) expenditures as incurred. R&D expenses are comprised of costs incurred in performing R&D activities,
including salaries, benefits, facilities, research-related overhead, sponsored research costs, contracted services, license fees,
expenses related to generating, filing, and maintaining intellectual property, and other external costs. Because the Company believes
that, under its current process for developing its products, the viability of the products is essentially concurrent with the establishment
of technological feasibility, no costs have been capitalized to date.
In-process Research and Development
The Company records in-process R&D
projects acquired in asset acquisitions that have not reached technological feasibility and which have no alternative future use.
For in-process R&D projects acquired in business combinations, the Company capitalizes the in-process R&D project and periodically
evaluates this asset for impairment until the R&D process has been completed. Once the R&D process is complete, the Company
amortizes the R&D asset over its remaining useful life. At March 31, 2019 and December 31, 2018, there is $3,912,314 of in-process
R&D, as part of intangible assets and in-process R&D on the Condensed Consolidated Balance Sheet.
EYEGATE PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
March 31, 2019
|
2.
|
Summary of Significant Accounting Policies - (continued)
|
Intangible Assets
The Company records intangible assets acquired
in asset acquisitions of proprietary technology. The Company capitalizes intangible assets, amortizes them over the estimated useful
life, and periodically evaluates the assets for impairment. At March 31, 2019 and December 31, 2018, there is $237,500 and $243,750
of net intangible assets, respectively, as part of intangible assets and in-process R&D on the Condensed Consolidated Balance
Sheet.
Accrued Clinical Expenses
As part of the Company’s process
of preparing the Condensed Consolidated Financial Statements, the Company is required to estimate its accrued expenses. This process
includes reviewing open contracts and purchase orders, communicating with its applicable personnel to identify services that have
been performed on its behalf and estimating the level of service performed and the associated costs incurred for the service when
the Company has not yet been invoiced or otherwise notified of actual costs. The majority of the Company’s service providers
invoice monthly in arrears for services performed. The Company makes estimates of its accrued expenses as of each balance sheet
date in the financial statements based on facts and circumstances known at the time. The Company periodically confirms the accuracy
of these estimates with the service providers and makes adjustments if necessary.
Related Party Transactions
The Company has entered into certain related-party
transactions, making payments for services to one vendor, eight consultants and two public universities for the three months ending
March 31, 2019, all of whom also are stockholders of the Company. These transactions generally are ones that involve a stockholder
or option holder of the Company to whom we also make payments during the year, typically as a consultant or a service provider.
The amounts recorded or paid are not material to the accompanying Condensed Consolidated Financial Statements.
Net Income (Loss) per Share
Basic net income (loss) per share is computed
by dividing net income (loss) available to common shareholders by the weighted-average number of common shares outstanding for
the period. Diluted net income (loss) per share is computed by dividing net income (loss) available to common shareholders by the
weighted-average number of common shares outstanding for the period plus potential dilutive common equivalent shares.
Dilutive common equivalent shares consist
of stock options, warrants, and preferred stock and are calculated using the treasury stock method, which assumes the repurchase
of common shares at the average market price during the period. Under the treasury stock method, options and warrants will have
a dilutive effect when the average price of common stock during the period exceeds the exercise price of options or warrants. Stock
options in the amount of 2,777,416 and warrants in the amount of 31,772,340 were excluded from the calculation of diluted net income
per share since they did not have a dilutive effect. Common equivalent shares do not qualify as participating securities. In periods
where the Company records a net loss, potential common stock equivalents are not included in the calculation of diluted net loss
per share as their effect would be anti-dilutive.
|
|
March 31,
2019
(unaudited)
|
|
|
March 31,
2018
(unaudited)
|
|
Common Stock Warrants
|
|
|
40,844,086
|
|
|
|
9,455,961
|
|
Employee Stock Options
|
|
|
2,777,416
|
|
|
|
2,167,003
|
|
Preferred Stock
|
|
|
12,787,500
|
|
|
|
-
|
|
Total Shares of Common Stock Issuable
|
|
|
56,409,002
|
|
|
|
11,622,964
|
|
Fair Value of Financial Instruments
The carrying amounts of all current assets
and current liabilities approximate their fair values due to the short-term nature of these items. As of March 31, 2019 and December
31, 2018, the fair value of the Company’s contingent consideration was $1,210,000 and $1,210,000, respectively.
At March 31, 2019 and December 31, 2018,
the Company had no other assets or liabilities that are subject to fair value methodology and estimation in accordance with U.S.
GAAP.
EYEGATE PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
March 31, 2019
|
2.
|
Summary of Significant Accounting Policies - (continued)
|
Revenue Recognition
The Company’s revenues are generated
primarily through arrangements which generally contain multiple elements, or deliverables, including licenses and R&D activities
to be performed by the Company on behalf of the licensor or grantor. Payments to EyeGate under these arrangements typically include
one or more of the following: (1) nonrefundable, upfront license fees, (2) funding of discovery research efforts on a
full-time equivalent basis, (3) reimbursement of research, development and intellectual property costs, (4) milestone
payments, and (5) royalties on future product sales.
On July 9, 2015, the Company entered into
an exclusive, worldwide licensing agreement with a subsidiary of Bausch Health Companies, Inc. (“BHC”), through which
the Company granted to BHC an exclusive, worldwide commercial and manufacturing right to the Company’s EGP-437 Combination
Product in the field of anterior uveitis, as well as a right of last negotiation to license its EGP-437 Combination Product for
indications other than anterior uveitis (the “BHC Agreement”). Under the BHC Agreement, BHC paid to the Company an
initial upfront payment of $1.0 million and the Company was eligible to receive milestone payments totaling up to $32.5 million,
upon and subject to the achievement of certain specified development and commercial progress of the EGP-437 Combination Product
for the treatment of anterior uveitis. The Company received milestone payments totaling $5.4 million through March 31, 2019. The
Company received payments both when it crossed certain thresholds on the way to each milestone, as well as once it achieved each
milestone. The Company is entitled to retain all of these payments. Effective March 14, 2019, this license agreement was voluntarily
terminated by BHC reinstating to the Company all of the rights and privileges of the EGP-437 platform. Upon termination of this
agreement, all amounts remaining in deferred revenue were recognized as revenue, as the Company no longer had any remaining performance
obligations.
On February 21, 2017, the Company entered
into another exclusive, worldwide licensing agreement with a subsidiary of BHC (the “New BHC Agreement”), through which
the Company granted BHC exclusive, worldwide commercial and manufacturing rights to its EGP-437 Combination Product in the field
of ocular iontophoretic treatment for post-operative ocular inflammation and pain in ocular surgery patients (the “New Field”).
Under the New BHC Agreement, BHC paid the Company an initial upfront payment of $4.0 million, and the Company was eligible to receive
milestone payments totaling up to approximately $99.0 million, upon and subject to the achievement of certain specified developmental
and commercial progress of the EGP-437 Combination Product for the New Field. The Company received milestone payments totaling
$3.4 million through March 31, 2019. The Company received payments both when it crossed certain thresholds on the way to each milestone,
as well as once it achieved each milestone. The Company is entitled to retain all of these payments. Effective March 14, 2019,
this license agreement was voluntarily terminated by BHC reinstating to the Company all of the rights and privileges of the EGP-437
platform. Upon termination of this agreement, all amounts remaining in deferred revenue were recognized as revenue, as the Company
no longer had any remaining performance obligations.
In May 2014, the FASB issued ASU No. 2014-09,
Revenues from Contracts with Customers
(“Topic 606”), as subsequently amended, that outlines a single comprehensive
model for entities to use in accounting for revenue arising from contracts with customers and supersedes most recent revenue recognition
guidance, including industry-specific guidance. The core principle of the revenue model is that an entity recognizes revenue to
depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity
expects to be entitled in exchange for those goods or services. This standard is effective for public companies for years ending
after December 15, 2017, with early adoption permitted.
The Company did not elect to early adopt
and adopted the new standard on January 1, 2018, using the modified retrospective method, which resulted in a cumulative effect
adjustment in the amount of $9.5 million to beginning 2018 accumulated deficit and to deferred and unbilled revenue for the BHC
contracts impacted by the adoption of the new standard. The changes to the method and/or timing of the Company’s revenue
recognition associated with the adoption of the new standard primarily relate to the determination that there is one performance
obligation in each contract with BHC and that the license combined with the R&D services is the performance obligation.
EYEGATE PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
March 31, 2019
|
2.
|
Summary of Significant Accounting Policies - (continued)
|
The Company recognizes revenue when its
customer obtains control of promised services, in an amount that reflects the consideration which the Company expects to receive
in exchange for those services. To determine whether arrangements are within the scope of this new guidance, the Company performs
the following five steps: (i) identifies the contract with a customer; (ii) identifies the performance obligations in the contract;
(iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and
(v) recognizes revenue when (or as) the Company satisfies its performance obligation. The Company applies the five-step model to
contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services
it transfers to the customer. Upon adoption of ASU No. 2014-09, the Company recognizes revenue from the transaction price applied
to each single performance obligation over time as milestones are reached for each performance obligation. The Company only recognizes
revenue on those milestones that are within the Company’s control and any constrained variable consideration that requires
regulatory approval will only be included in the transaction price when performance is complete.
The below table represents the changes
in the Company’s contract liabilities:
|
|
March 31,
2019
|
|
|
December 31,
2018
|
|
Contract Liabilities:
|
|
|
|
|
|
|
|
|
Deferred Revenue
|
|
$
|
-
|
|
|
$
|
2,686,000
|
|
|
|
Three Months
Ended
|
|
|
|
March 31,
2019
|
|
Revenue recognized in the period from:
|
|
|
|
Amounts included in contract liability at the beginning of the period
|
|
$
|
2,686,000
|
|
In addition, the Company may receive government
grant funds for specified ocular therapeutic research activities. Revenue under these grants will be recorded when the Company
performs the activities specified by the terms of each grant and is entitled to the funds.
Recent Accounting Pronouncements
In February 2016, the FASB issued ASU No.
2016-02,
Leases
, which is effective for fiscal years, and interim periods within those years, beginning after December 15,
2018, with early adoption permitted. Under ASU No. 2016-02, lessees are required to recognize for all leases at the commencement
date a lease liability, which is a lessee’s obligation to make lease payments arising from a lease measured on a discounted
basis, and the right-to-use assets, which are asset that represents the lessee’s right to use or control the use of a specified
asset for the lease term. The Company adopted the new standard effective January 1, 2019 using the modified retrospective method
and recorded right-of-use leased assets and corresponding liabilities of approximately $0.137 million in the first quarter of 2019.
On January 26, 2017, the FASB issued ASU
No. 2017-04,
Intangibles
—
Goodwill and Other
, which simplifies the accounting for goodwill impairment. The guidance
removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment
will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount
of goodwill. All other goodwill impairment guidance will remain largely unchanged. Entities will continue to have the option to
perform a qualitative assessment to determine if a quantitative impairment test is necessary. The same one-step impairment test
will be applied to goodwill at all reporting units, even those with zero or negative carrying amounts. Entities will be required
to disclose the amount of goodwill at reporting units with zero or negative carrying amounts. The new standard is effective for
the Company on January 1, 2020. The new standard is required to be applied prospectively. Early adoption is permitted for any impairment
tests performed after January 1, 2017. The Company did not early adopt ASU No. 2017-04 prior to its December 2018 impairment evaluation
and is evaluating the effect that ASU No. 2017-04 will have on its Consolidated Financial Statements and related disclosures.
EYEGATE PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
March 31, 2019
|
3.
|
Property and Equipment
|
Property and equipment at March 31, 2019
and December 31, 2018 consists of the following:
|
|
Estimated
Useful Life
(Years)
|
|
|
March 31,
2019
(unaudited)
|
|
|
December 31,
2018
|
|
Laboratory Equipment
|
|
3
|
|
|
$
|
62,576
|
|
|
$
|
62,576
|
|
Office Furniture
|
|
5
|
|
|
|
14,430
|
|
|
|
14,430
|
|
Leasehold Improvements
|
|
2
|
|
|
|
22,569
|
|
|
|
22,569
|
|
Total Property and Equipment, Gross
|
|
|
|
|
|
|
99,575
|
|
|
|
99,575
|
|
Less: Accumulated Depreciation
|
|
|
|
|
|
|
62,725
|
|
|
|
56,057
|
|
Total Property and Equipment, Net
|
|
|
|
|
|
$
|
36,850
|
|
|
$
|
43,518
|
|
Depreciation expense was $6,668 and $7,966
for the three-month periods ended March 31, 2019 and 2018, respectively.
Accrued expenses at March 31, 2019 and
December 31, 2018 consist of the following:
|
|
March 31,
2019
(unaudited)
|
|
|
December 31,
2018
|
|
Payroll and Benefits
|
|
$
|
345,423
|
|
|
$
|
722,178
|
|
Professional Fees
|
|
|
112,284
|
|
|
|
165,894
|
|
Clinical Trials
|
|
|
111,631
|
|
|
|
212,540
|
|
Consulting
|
|
|
5,556
|
|
|
|
9,401
|
|
Short-Term Portion of Capital Financing Obligation
|
|
|
3,143
|
|
|
|
4,715
|
|
Total Accrued Expenses
|
|
$
|
578,037
|
|
|
$
|
1,114,728
|
|
The Company has no indebtedness other than
trade and accounts payable and capital financing obligations in the ordinary course of business at March 31, 2019 and December
31, 2018.
EYEGATE PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
March 31, 2019
|
6.
|
Intangible Assets and In-Process R&D
|
Intangible assets at March 31, 2019 consist
of the rights to trade-secrets and know-how related to the manufacturing of the EyeGate Ocular Bandage Gel (“OBG”).
During the third quarter of 2018, the Company entered into an intellectual property license agreement with SentrX Animal Care,
Inc. (“SentrX”) with respect to certain rights relating to the manufacturing of the EyeGate OBG product. The intangible
assets were recorded at $250,000, representing the upfront payment paid to SentrX. Additionally, SentrX is eligible to receive
milestone payments totaling up to $4.75 million, upon and subject to the achievement of certain specified development and commercial
milestones. These future milestone payments to SentrX will increase the carrying value of the intangible assets. The Company’s
intangible assets are amortized on a straight-line basis over the estimated useful lives. Additionally, in-process R&D at March
31, 2019 and December 31, 2018 consists of projects acquired from the acquisition of Jade that have not reached technological feasibility
and which have no alternative future use. Once the R&D process is complete, the Company will amortize the R&D asset over
its remaining useful life. The Company periodically evaluates these assets for impairment.
Intangible assets and in-process R&D
at March 31, 2019 and December 31, 2018 consists of the following:
|
|
Estimated Useful
Life (Years)
|
|
|
March 31, 2019
(unaudited)
|
|
|
December 31,
2018
|
|
Trade Secrets
|
|
10
|
|
|
$
|
250,000
|
|
|
$
|
250,000
|
|
Less: Accumulated Amortization
|
|
|
|
|
|
|
(12,500
|
)
|
|
|
(6,250
|
)
|
Intangible Assets, Net
|
|
|
|
|
|
|
237,500
|
|
|
|
243,750
|
|
In-Process R&D
|
|
|
|
|
|
|
3,912,314
|
|
|
|
3,912,314
|
|
Total Intangible Assets and In-Process R&D, Net
|
|
|
|
|
|
$
|
4,149,814
|
|
|
$
|
4,156,064
|
|
Amortization expense on intangible assets
was $6,250 and $0 for the three-month periods ended March 31, 2019 and 2018, respectively.
On May 24, 2016, the Company entered into
an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent”),
to create an at the market equity program under which the Company can from time to time offer and sell up to 1,319,289 shares of
its Common Stock through the Sales Agent. On February 21, 2017, the Company authorized the Sales Agent to restart sales under the
ATM Agreement for maximum aggregate gross proceeds of up to $3,285,798. During the first quarter of 2017, the Company sold 642,150
shares of Common Stock under this agreement for total net proceeds to the Company from this offering, after deducting the placement
agent fees and offering expenses, of approximately $1.8 million. No further shares of Common Stock have been sold pursuant to the
ATM Agreement. On June 14, 2017, the Company closed on the sale of its equity securities in connection with a public offering,
described below, and as a result, the Company is restricted from issuing any shares pursuant to the ATM Agreement for a period
of twenty-four months following the closing date of the offering. However, this restriction is suspended for any sale of shares
of Common Stock under the ATM Agreement that is above $3.00 per share.
On June 14, 2017, the Company completed
a public offering of 5,336,667 shares of Common Stock and 1,995 shares of Series B Preferred Stock (convertible into 1,330,000
shares of Common Stock), along with warrants to purchase 6,666,667 shares of Common Stock. The total net proceeds to the Company
from the offering, after deducting the placement agent fees and offering expenses, were approximately $8.8 million. Additionally,
the investors received, for each share of Common Stock, or for each share of Common Stock issuable upon conversion of a share of
Series B Preferred Stock purchased in the public offering, warrants to purchase one share of Common Stock at an exercise price
of $1.50 per share, which totaled warrants to purchase an aggregate of 6,666,667 shares of Common Stock. The warrants issued to
investors became initially exercisable immediately upon issuance and terminate on June 14, 2022, five years following the date
of issuance. Concurrently with the closing of the public offering, a holder elected to convert 675 shares of Series B Preferred
Stock into 450,000 shares of Common Stock. Subsequently, on June 15, 2017 and April 9, 2018, holders converted 1,320 shares of
Series B Preferred stock into 880,000 shares of Common Stock.
EYEGATE PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
March 31, 2019
|
7.
|
Capital Stock - (continued)
|
On April 17, 2018, the Company completed
a public offering of 14,730,000 shares of Common Stock and 6,536.4 shares of Series C Preferred Stock (convertible into 20,426,250
shares of Common Stock), along with warrants to purchase 35,156,250 shares of Common Stock. The total net proceeds to the Company
from the offering, after deducting the placement agent fees and offering expenses, were approximately $10.1 million. Additionally,
the investors received, for each share of Common Stock, or for each share of Common Stock issuable upon conversion of a share of
Series C Preferred Stock purchased in the public offering, warrants to purchase one share of Common Stock at an exercise price
of $0.32 per share, which totaled warrants to purchase an aggregate of 35,156,250 shares of Common Stock. The warrants issued to
investors became initially exercisable immediately upon issuance and terminate on April 17, 2023, five years following the date
of issuance. Concurrently with the closing of the public offering, a holder elected to convert 1,400 shares of Series C Preferred
Stock into 4,375,000 shares of Common Stock. Subsequently, on April 18, 2018, April 23, 2018, and April 30, 2018, holders converted
1,044.4 shares of Series C Preferred stock into 3,263,750 shares of Common Stock.
At March 31, 2019, the Company
had 120,000,000 authorized shares of Common Stock, $0.01 par value, of which 45,575,737 shares were outstanding. Included in
the outstanding shares number at March 31, 2019 and December 31, 2018 is 1,785,000 restricted shares that were granted, but
not yet formally issued. At March 31, 2019, the Company had 9,994,184 authorized shares of Preferred Stock, $0.01 par value,
of which 3,750 shares were designated as Series A Preferred Stock and 0 shares are issued and outstanding, 10,000 shares
were designated as Series B Preferred Stock and 0 shares are issued and outstanding, and 10,000 shares were designated as
Series C Preferred Stock and 4,092 shares are issued and outstanding. At March 31, 2019, there were 0 shares of Common
Stock underlying the outstanding shares of Series A Preferred Stock, 0 shares of Common Stock underlying the outstanding
shares of Series B Preferred Stock, and 12,787,500 shares of Common Stock underlying the outstanding shares of Series C
Preferred Stock.
The following is a summary of warrant activity
for the three months ended March 31, 2019 and 2018:
|
|
Number of
Warrants
|
|
|
Weighted Average
Exercise
Price
|
|
|
Weighted Average
Remaining
Term in Years
|
|
Outstanding at December 31, 2018
|
|
|
40,844,086
|
|
|
$
|
1.00
|
|
|
|
4.05
|
|
Outstanding at March 31, 2019
|
|
|
40,844,086
|
|
|
|
1.00
|
|
|
|
3.80
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at December 31, 2017
|
|
|
9,455,961
|
|
|
|
3.26
|
|
|
|
4.23
|
|
Outstanding at March 31, 2018
|
|
|
9,455,961
|
|
|
$
|
3.26
|
|
|
|
3.98
|
|
All of the warrant agreements provide for a cashless exercise
in the event a registration statement covering the issuance of the shares of common stock underlying the warrants is not effective,
whereby the number of warrants to be issued will be reduced by the number of shares which could be purchased from the proceeds
of the exercise of the respective warrant. The outstanding warrants expire from 2020 through 2025.
EYEGATE PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
March 31, 2019
In 2005, the Company approved the 2005 Equity Incentive Plan
(the “2005 Plan”). The 2005 Plan provides for the granting of options, restricted stock or other stock-based awards
to employees, officers, directors, consultants and advisors. During 2010, the maximum number of shares of Common Stock that may
be issued pursuant to the 2005 Plan was increased to 891,222 shares. The Board of Directors (the “Board”) is responsible
for administration of the 2005 Plan. The Company’s Board determines the term of each option, the option exercise price, the
number of shares for which each option is granted and the rate at which each option is exercisable. Incentive stock options may
be granted to any officer or employee at an exercise price per share of not less than the fair value per common share on the date
of the grant (not less than 110% of fair value in the case of holders of more than 10% of the Company’s voting stock) and
with a term not to exceed ten years from the date of the grant (five years for incentive stock options granted to holders of more
than 10% of the Company’s voting stock). Nonqualified stock options may be granted to any officer, employee, consultant or
director at an exercise price per share of not less than the par value per share. Following adoption of the 2014 Equity Incentive
Plan (the “2014 Plan”), no further grants were made under the 2005 Plan. General terms of the 2014 Plan remain the
same as that of the 2005 Plan.
The Company’s Board adopted the 2014 Plan and the Employee
Stock Purchase Plan (the “ESPP”) and the Company’s Stockholders approved the 2014 Plan and the ESPP Plan in February
2015. As of March 31, 2019, the maximum number of shares of Common Stock that may be issued pursuant to the 2014 Plan and the ESPP
was 8,390,123 and 170,567 shares, respectively.
In January 2019, the number of shares of common stock issuable
under the 2014 Plan automatically increased by 350,000 shares pursuant to the terms of the 2014 Plan. These additional shares are
included in the total of 8,390,123 shares issuable under the 2014 Plan.
The following is a summary of stock option activity for the
three months ended March 31, 2019 and 2018:
|
|
Number of
Options
|
|
|
Weighted- Average
Exercise Price
|
|
|
Weighted-Average
Contractual Life
(In Years)
|
|
Outstanding at December 31, 2018
|
|
|
2,076,153
|
|
|
$
|
2.28
|
|
|
|
6.51
|
|
Granted
|
|
|
750,000
|
|
|
|
0.48
|
|
|
|
|
|
Expired
|
|
|
(48,737
|
)
|
|
|
1.08
|
|
|
|
|
|
Outstanding at March 31, 2019
|
|
|
2,777,416
|
|
|
$
|
1.81
|
|
|
|
7.34
|
|
Exercisable at March 31, 2019
|
|
|
1,593,224
|
|
|
$
|
2.70
|
|
|
|
5.78
|
|
Vested and Expected to Vest at March 31, 2019
|
|
|
2,777,416
|
|
|
$
|
1.81
|
|
|
|
7.34
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at December 31, 2017
|
|
|
1,893,003
|
|
|
$
|
2.49
|
|
|
|
5.40
|
|
Granted
|
|
|
275,500
|
|
|
|
0.57
|
|
|
|
|
|
Forfeited
|
|
|
(1,500
|
)
|
|
|
0.83
|
|
|
|
|
|
Outstanding at March 31, 2018
|
|
|
2,167,003
|
|
|
$
|
2.24
|
|
|
|
5.49
|
|
Exercisable at March 31, 2018
|
|
|
1,272,677
|
|
|
$
|
2.72
|
|
|
|
3.90
|
|
Vested and Expected to Vest at March 31, 2018
|
|
|
2,167,003
|
|
|
$
|
2.24
|
|
|
|
5.49
|
|
During the three months
ended March 31, 2019 and March 31, 2018, the Board approved the grant of options to purchase 750,000 and 275,500 shares of its
Common Stock, respectively. All option grants were pursuant to the 2014 Plan. In general, options granted under the 2014 Plan vest
with respect to one-third of the underlying shares on the one-year anniversary of the grant date and the remainder ratably over
a 24-month period.
EYEGATE PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
March 31, 2019
|
9.
|
Equity Incentive Plan - (continued)
|
For the three months ended March 31, 2019
and 2018, the fair value of each option grant has been estimated on the date of grant using the Black-Scholes Option Pricing Model
with the following weighted-average assumptions:
|
|
2019
|
|
|
2018
|
|
Risk-Free Interest Rate
|
|
|
1.82%
|
|
|
|
1.82%
|
|
Expected Life
|
|
|
5.00 years
|
|
|
|
7.00 years
|
|
Expected Volatility
|
|
|
152%
|
|
|
|
159%
|
|
Expected Dividend Yield
|
|
|
0%
|
|
|
|
0%
|
|
Using the Black-Scholes Option Pricing
Model, the estimated weighted average fair value of an option to purchase one share of common stock granted during the three months
ended March 31, 2019 and 2018 was $0.47 and $0.55, respectively.
The following is a summary of restricted
stock activity for the three months ended March 31, 2019 and March 31, 2018:
|
|
Number of
Shares
|
|
|
Weighted- Average
Grant Date Fair Value
|
|
|
Weighted- Average
Remaining
Recognition Period
|
|
Nonvested Outstanding at December 31, 2018
|
|
|
1,822,132
|
|
|
$
|
0.59
|
|
|
|
|
|
Released/Vested
|
|
|
(7,957
|
)
|
|
|
1.52
|
|
|
|
|
|
Nonvested Outstanding at March 31, 2019
|
|
|
1,814,175
|
|
|
$
|
0.59
|
|
|
|
2.01
|
|
Nonvested Outstanding at December 31, 2017
|
|
|
103,000
|
|
|
|
1.52
|
|
|
|
|
|
Released/Vested
|
|
|
(37,190
|
)
|
|
|
1.52
|
|
|
|
|
|
Nonvested Outstanding at March 31, 2018
|
|
|
65,810
|
|
|
$
|
1.52
|
|
|
|
1.85
|
|
The total stock-based compensation expense for employees and
non-employees is included in the accompanying Condensed Consolidated Statements of Operations and as follows:
|
|
Three Months Ended
March 31,
|
|
|
|
2019
|
|
|
2018
|
|
Research and Development
|
|
$
|
64,539
|
|
|
$
|
57,078
|
|
General and Administrative
|
|
|
168,367
|
|
|
|
88,469
|
|
Total Stock-Based Compensation Expense
|
|
$
|
232,906
|
|
|
$
|
145,547
|
|
The fair value of options granted for the
three months ended March 31, 2019 and March 31, 2018 was approximately $355,300 and $151,200, respectively. As of March 31, 2019
and March 31, 2018, there was approximately $1,358,000 and $945,000 of total unrecognized compensation expense related to unvested
stock-based compensation arrangements granted, which cost is expected to be recognized over a weighted-average period of 2.19 and
1.57 years, respectively. The aggregate intrinsic value of stock options outstanding and exercisable at March 31, 2019 and March
31, 2018 was approximately $0 and $0, respectively.
At March 31, 2019, there were 4,033,056
shares available under the 2014 Plan and 117,090 shares available under the Company’s ESPP.
EYEGATE PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
March 31, 2019
|
10.
|
Commitments and Contingencies
|
Leases
The Company is a party to a real property
operating lease for the rental of office space in Waltham, Massachusetts of up to 4,516 square feet, that is used for its corporate
headquarters. This lease terminates in December 2019. On July 6, 2016, the Company entered into a real property operating lease
for office and laboratory space of approximately 2,300 square feet in Salt Lake City, Utah. This lease terminates in June 2019.
Operating lease assets and liabilities
are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not yet
paid. Operating lease assets represent the Company’s right to use an underlying asset and are based upon the operating lease
liabilities adjusted for prepayments or accrued lease payments. To determine the present value of lease payments not yet paid,
the Company estimated incremental secured borrowing rates corresponding to the maturities of the leases. The Company estimated
a rate of 10% based on prevailing financial market conditions, comparable company and credit analysis, and management judgment.
The Company recognizes expense for its leases on a straight-line basis over the lease term.
Maturities of lease liabilities were as
follows as of March 31, 2019:
|
|
Operating Leases
|
|
Remainder of 2019
|
|
$
|
101,500
|
|
Less: Imputed Interest
|
|
|
3,781
|
|
Present Value of Lease Liabilities
|
|
$
|
97,719
|
|
License Agreements
The Company is a party to five license
agreements as described below. These license agreements require the Company to pay royalties or fees to the licensor based on revenue
or milestones related to the licensed technology.
On February 15, 1999, the Company entered
in to an exclusive worldwide license agreement with the University of Miami School of Medicine to license technology relating to
the Company’s EyeGate® II Delivery System. This agreement, which was amended in December 2005, requires the Company to
pay to the University of Miami an annual license fee of $12,500. This license also requires payments to the University of Miami
upon the Company’s achievement of certain milestones. Unless terminated pursuant to the license agreement, this license will
expire 12 years after the date of the first commercial sale of a product containing the licensed technology.
On July 23, 1999, the Company entered into
a perpetual Transaction Protocol agreement with Francine Behar-Cohen to acknowledge the Company’s right to use certain patents
that Ms. Behar-Cohen had certain ownership rights with respect to and which are used in the Company’s EGP-437 Combination
Product. The agreement also provides for the Company to pay Ms. Behar-Cohen a fee based on a percentage of the pre-tax turnover
generated from sales of the Company’s EGP-437 Combination Product relating to its inclusion of the EyeGate® II Delivery
System. The fees due under the agreement expired in January 2018, but the Company continues to maintain its rights under the agreement.
On September 12, 2013, Jade entered into
an agreement with BioTime, Inc. granting to it the exclusive worldwide right to commercialize cross-linked thiolated carboxymethyl
hyaluronic acid (“CMHA-S”) for ophthalmic treatments in humans. The agreement calls for a license issue fee paid
to BioTime of $50,000 and requires the Company (through its Jade subsidiary) to pay an annual fee of $30,000 and royalties to BioTime
based on revenue relating to any product incorporating the CMHA-S technology. The agreement expires when patent protection
for the CMHA-S technology lapses.
EYEGATE PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
March 31, 2019
|
10.
|
Commitments and Contingencies - (continued)
|
On June 17, 2016, the Company entered into
an exclusive worldwide license agreement with the University of Utah Research Foundation to further the commercial development
of the NASH technology, together with alkylated HA. The agreement calls for payments due to the University of Utah, consisting
of a license grant fee of $15,000 due within 30 days of signing, and an annual licensing fee, initially $5,000, and escalating
ratably up to $20,000 in 2021.
On September 26, 2018, the Company entered
into an intellectual property licensing agreement (the “SentrX Agreement”) with SentrX, a veterinary medical device
company that develops and manufactures veterinary wound care products. Under the SentrX Agreement, the Company will in-license
the rights to trade-secrets and know-how related to the manufacturing of its EyeGate OBG. The SentrX Agreement will enable the
Company to pursue a different vendor with a larger capacity for manufacturing and an FDA-inspected facility for commercialization
of a product for human use. Under the SentrX Agreement, the Company paid SentrX an upfront payment of $250,000 recorded as intangible
assets on the Condensed Consolidated Balance Sheet. SentrX is eligible to receive milestone payments totaling up to $4.75
million, upon and subject to the achievement of certain specified developmental and commercial milestones. These future milestone
payments to SentrX will increase the carrying value of the intangible assets.
|
11.
|
Employee Benefit Plans
|
The Company has an employee benefit plan for its United States-based
employees under Section 401(k) of the Internal Revenue Code. The Plan allows all eligible employees to make contributions up to
a specified percentage of their compensation. Under the Plan, the Company may, but is not obligated to, match a portion of the
employee contribution up to a defined maximum. As a result of the 401(k) plan compliance review for the year ended December 31,
2018, the Company will contribute approximately $29,700 to eligible employees. The Company made no matching contribution for the
three months ended March 31, 2019 and 2018.
|
12.
|
Weighted-Average Shares
|
The Company calculated weighted-average
shares as follows:
|
|
Three Months Ended
March 31,
|
|
|
|
2019
|
|
|
2018
|
|
Weighted-Average Shares Outstanding- Basic
|
|
|
43,762,539
|
|
|
|
17,257,255
|
|
Warrants (in the money)
|
|
|
9,071,746
|
|
|
|
-
|
|
Preferred Stock (common equivalent)
|
|
|
12,787,500
|
|
|
|
-
|
|
Restricted Stock Awards (nonvested)
|
|
|
1,814,175
|
|
|
|
-
|
|
Weighted-Average Shares Outstanding- Diluted
|
|
|
67,435,960
|
|
|
|
17,257,255
|
|
For the three months ended March 31, 2018, no effect has been
given to the shares of common stock issuable upon the conversion or exercise of dilutive securities, as the Company’s net
loss would make the effect anti-dilutive.